== Ivermectin ==

"Randomized Control Trials" subset of all papers mentioned

https://c19ivm.org/chowdhury.html 
 . A Comparative Study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin Therapy on COVID-19 Patients
  . Chowdhury et al., Eurasian Journal of Medicine and Oncology, doi:10.14744/ejmo.2021.16263
  . '''Comments''' Not double blind, Ivermectin combined with Doxycyline versus Hydroxychloroquine with Azithromycin, hence comparing two combinations
  . '''not Ivermectin only versus placebo''', nor Ivermectin+X versus X alone

https://c19ivm.org/mahmud.html
 . Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial
  . Mahmud et al., Journal of International Medical Research, doi:10.5061/dryad.qjq2bvqf6
  . '''Comments''' Better designed, Double-blind combination test, 3 deaths in doxy-only control group.  This is promising, but 3 deaths is NOT enough to make the p=0.25 claim

https://c19ivm.org/ahmed.html
 . A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness
  . Ahmed et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.11.191
  . '''Comments''' Not double blind, PCR testing started late so "time to" tests seem subjective
 
https://c19ivm.org/chaccour.html
 . The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial
  . Chaccour et al., EClinicalMedicine, doi:10.1016/j.eclinm.2020.100720
  . 12 patients in each treatment wing, too small to make valid conclusions
 
https://c19ivm.org/babalola.html
 . Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos
  . Babalola et al., QJM: An International Journal of Medicine, doi:10.1093/qjmed/hcab035
  . 20 patients in each treatment wing, too small to make valid conclusions

https://c19ivm.org/ravikirti.html
 . Ivermectin as a potential treatment for mild to moderate COVID-19: A double blind randomized placebo-controlled trial
  . Ravikirti et al., Journal of Pharmacy & Pharmaceutical Sciences, doi:10.18433/jpps32105
  . 55 / 57 patients in each treatment wing, more than most

https://c19ivm.org/bukhari.html
 . Efficacy of Ivermectin in COVID-19 Patients with Mild to Moderate Disease
  . Bukhari et al., medRxiv, doi:10.1101/2021.02.02.21250840
  .  41 / 45 patients in each treatment wing

https://c19ivm.org/mohan.html
 . Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): a single-centre randomized, placebo-controlled trial
  . Mohan et al., Journal of Infection and Chemotherapy, doi:10.1016/j.jiac.2021.08.021

https://c19ivm.org/biber.html


https://c19ivm.org/lopezmedina.html


https://c19ivm.org/chahla.html
 . 87%

https://c19ivm.org/faisal.html
 . 68%

https://c19ivm.org/aref.html
 . 63%

https://c19ivm.org/krolewiecki.html
 . ''-152%''

https://c19ivm.org/vallejos2.html
 . ''-33%''

https://c19ivm.org/togetherivm.html
 . 43%
 . Effect of Early Treatment with Ivermectin among Patients with Covid-19
  . Reis et al., New England Journal of Medicine, doi:10.1056/NEJMoa2115869
 . '''84 negative issues, 36 critical, 23 serious, 21 major   SERIOUS BULLSHIT PROBLEM'''

https://c19ivm.org/buonfrate.html
 . ''-211%''


https://c19ivm.org/abbas2.html
 . ''-4%''


https://c19ivm.org/manomaipiboon.html
 . 43%


https://c19ivm.org/delarocha.html
 . ''-187%''


https://c19ivm.org/rezai3.html
 . ''-5%''


https://c19ivm.org/mirahmadizadeh.html
 . 67%


https://c19ivm.org/schilling.html
 . 67%

https://c19ivm.org/covidoutivm.html
 . ''-197%''